The main reasons for performing amyloid PET were a clinical suspicion of AD in combination with either a negative or an unclear (i.e. isolated positive or borderline Aβ1-42 or tau) CSF profile (117 patients, 57%) or the absence of CSF samples (55 patients, 27%). Here, MAPT is linked to Alzheimer disease.